BIIB [NASD]
Biogen Inc.
IndexNDX, S&P 500 P/E12.91 EPS (ttm)20.92 Insider Own0.10% Shs Outstand143.80M Perf Week1.27%
Market Cap38.31B Forward P/E16.36 EPS next Y16.51 Insider Trans-7.28% Shs Float143.01M Perf Month0.12%
Income3.05B PEG8.80 EPS next Q3.38 Inst Own88.60% Short Float / Ratio1.38% / 2.01 Perf Quarter-3.45%
Sales10.17B P/S3.77 EPS this Y100.60% Inst Trans0.85% Short Interest1.98M Perf Half Y37.69%
Book/sh93.17 P/B2.90 EPS next Y6.29% ROA12.40% Target Price321.07 Perf Year27.75%
Cash/sh34.48 P/C7.83 EPS next 5Y1.47% ROE24.70% 52W Range187.16 - 311.88 Perf YTD-2.67%
Dividend- P/FCF33.49 EPS past 5Y3.70% ROI9.80% 52W High-13.58% Beta0.18
Dividend %- Quick Ratio2.60 Sales past 5Y-3.70% Gross Margin77.60% 52W Low44.01% ATR5.82
Employees8725 Current Ratio3.00 Sales Q/Q-6.90% Oper. Margin25.20% RSI (14)50.96 Volatility2.07% 2.13%
OptionableYes Debt/Eq0.47 EPS Q/Q51.60% Profit Margin29.90% Rel Volume0.26 Prev Close269.98
ShortableYes LT Debt/Eq0.47 EarningsFeb 15 BMO Payout0.00% Avg Volume985.56K Price269.52
Recom2.20 SMA201.57% SMA50-2.59% SMA2006.78% Volume221,419 Change-0.17%
Oct-26-22Upgrade Goldman Neutral → Buy $220 → $370
Oct-13-22Upgrade Stifel Hold → Buy $223 → $299
Oct-07-22Upgrade Argus Hold → Buy $300
Sep-28-22Upgrade Robert W. Baird Neutral → Outperform $224 → $340
Sep-28-22Upgrade Mizuho Neutral → Buy $207 → $270
Sep-28-22Upgrade BMO Capital Markets Market Perform → Outperform $217 → $360
Apr-18-22Upgrade Wells Fargo Equal Weight → Overweight $235 → $265
Mar-08-22Downgrade Stifel Buy → Hold $304 → $223
Mar-03-22Upgrade RBC Capital Mkts Sector Perform → Outperform $227 → $248
Feb-04-22Reiterated Wolfe Research Peer Perform $244 → $217
Show Previous Ratings
Mar-27-23 06:15PM
11:42AM
11:15AM
Mar-26-23 09:00AM
08:45AM
04:03PM Loading…
Mar-23-23 04:03PM
01:56PM
01:51PM
10:53AM
09:25AM
09:12AM
06:09AM
Mar-22-23 08:31PM
05:29PM
Mar-21-23 06:00PM
08:59AM Loading…
08:59AM
Mar-20-23 12:25PM
09:51AM
Mar-19-23 05:30AM
Mar-17-23 11:30AM
08:00AM
Mar-16-23 02:00PM
08:43AM
06:30AM
Mar-15-23 06:00PM
Mar-14-23 06:15PM
10:52AM
10:23AM
08:57AM
07:30AM
05:05PM Loading…
Mar-13-23 05:05PM
05:01PM
Mar-09-23 04:05PM
09:33AM
Mar-08-23 06:00PM
07:30AM
Mar-07-23 06:50AM
Mar-06-23 04:38PM
12:46PM
11:38AM
08:16AM
Mar-05-23 06:30PM
Mar-01-23 02:43PM
12:04PM
Feb-28-23 08:14PM
06:31PM
05:39PM
01:41PM
Feb-27-23 06:30PM
06:30PM
02:30PM
Feb-23-23 06:00AM
Feb-22-23 09:07PM
Feb-19-23 06:00AM
Feb-16-23 06:49PM
01:41PM
11:48AM
Feb-15-23 04:03PM
02:30PM
01:58PM
01:16PM
12:26PM
11:43AM
10:57AM
10:53AM
09:47AM
09:13AM
08:54AM
08:25AM
07:53AM
07:24AM
07:24AM
07:04AM
07:01AM
03:00AM
Feb-14-23 05:23PM
Feb-13-23 07:56AM
Feb-11-23 07:00AM
Feb-10-23 01:40PM
Feb-08-23 02:00PM
10:00AM
09:47AM
Feb-07-23 10:17AM
10:16AM
09:00AM
Feb-06-23 06:00PM
12:14PM
06:30AM
06:30AM
Feb-01-23 04:10PM
09:53AM
Jan-30-23 06:00PM
09:38AM
Jan-29-23 07:44PM
06:30PM
02:35PM
Jan-27-23 09:57AM
Jan-26-23 07:22PM
06:30PM
07:30AM
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Singhal PriyaHead of DevelopmentMar 02Option Exercise0.0029703,554Mar 06 06:13 PM
Singhal PriyaHead of DevelopmentFeb 17Option Exercise0.0046003,951Feb 22 05:07 PM
Kramer RobinChief Accounting OfficerFeb 17Option Exercise0.0051203,844Feb 22 05:01 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 17Option Exercise0.002,561010,147Feb 22 05:03 PM
Izzar RachidHead of Global Product Strat.Feb 17Option Exercise0.0076705,884Feb 22 04:57 PM
Gregory GingerEVP, Human ResourcesFeb 17Option Exercise0.001,792011,072Feb 22 04:54 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 17Option Exercise0.001,920046,840Feb 22 04:49 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 10Option Exercise0.004,023048,358Feb 14 09:46 PM
Gregory GingerEVP, Human ResourcesFeb 10Option Exercise0.003,290012,805Feb 14 09:44 PM
Izzar RachidHead of Global Product Strat.Feb 10Option Exercise0.001,96806,359Feb 14 09:41 PM
Kramer RobinChief Accounting OfficerFeb 10Option Exercise0.001,06103,932Feb 14 09:37 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 10Option Exercise0.003,256010,001Feb 14 09:25 PM
Murphy NicoleHead of Pharm Ops and TechFeb 10Option Exercise0.002,61106,379Feb 14 09:23 PM
Singhal PriyaHead of DevelopmentFeb 10Option Exercise0.001,21103,863Feb 14 09:21 PM
Kramer RobinChief Accounting OfficerDec 08Option Exercise0.0035002,368Dec 12 06:04 PM
Izzar RachidHead of Alzheimer's DiseaseDec 02Option Exercise0.001,71003,395Dec 06 06:37 PM
Murphy NicoleHead of Pharm Ops and TechDec 02Option Exercise0.0013102,807Dec 06 06:33 PM
Gregory GingerEVP, Human ResourcesNov 14Sale300.115,6101,683,6175,711Dec 12 08:00 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecOct 27Sale280.705,5321,552,83239,396Oct 28 07:19 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerSep 01Option Exercise0.004,74607,801Sep 06 07:31 PM
BIOGEN INC.10% OwnerAug 30Sale5.27100,000526,52023,652,466Aug 31 07:03 PM
BIOGEN INC.10% OwnerAug 29Sale5.33400,0002,130,72023,752,466Aug 31 07:03 PM
Murphy NicoleHead of Pharm Ops and TechAug 01Option Exercise0.001,08002,919Aug 03 05:40 PM
Kramer RobinChief Accounting OfficerJul 01Option Exercise0.0025202,092Jul 06 07:33 PM
Izzar RachidHead of Alzheimer's DiseaseJul 01Option Exercise0.0050402,258Jul 06 07:28 PM